112 related articles for article (PubMed ID: 21506898)
41. Insulin glargine and the risk of cancer.
Ahmed FA
Cardiovasc J Afr; 2010; 21(1):49. PubMed ID: 20224847
[No Abstract] [Full Text] [Related]
42. Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy.
Cammarota S; Bruzzese D; Catapano AL; Citarella A; De Luca L; Manzoli L; Masulli M; Menditto E; Mezzetti A; Riegler S; Putignano D; Tragni E; Novellino E; Riccardi G
Nutr Metab Cardiovasc Dis; 2014 Jan; 24(1):10-7. PubMed ID: 23806740
[TBL] [Abstract][Full Text] [Related]
43. Basal insulin and cardiovascular and other outcomes in dysglycemia.
; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
[TBL] [Abstract][Full Text] [Related]
44. A possible link between insulin glargine and malignancy: the facts.
Mollentze WF
Cardiovasc J Afr; 2009; 20(4):216-8; discussion 218-9. PubMed ID: 19701528
[No Abstract] [Full Text] [Related]
45. Long-acting insulin analogs and cancer.
Sciacca L; Vella V; Frittitta L; Tumminia A; Manzella L; Squatrito S; Belfiore A; Vigneri R
Nutr Metab Cardiovasc Dis; 2018 May; 28(5):436-443. PubMed ID: 29609864
[TBL] [Abstract][Full Text] [Related]
46. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
47. Insulin glargine (Lantus) and cancer risk.
Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
[No Abstract] [Full Text] [Related]
48. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.
Garg SK; Gottlieb PA; Hisatomi ME; D'Souza A; Walker AJ; Izuora KE; Chase HP
Diabetes Res Clin Pract; 2004 Oct; 66(1):49-56. PubMed ID: 15364161
[TBL] [Abstract][Full Text] [Related]
49. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
Cukierman-Yaffe T; Bosch J; Diaz R; Dyal L; Hancu N; Hildebrandt P; Lanas F; Lewis BS; Marre M; Yale JF; Yusuf S; Gerstein HC;
Lancet Diabetes Endocrinol; 2014 Jul; 2(7):562-72. PubMed ID: 24898834
[TBL] [Abstract][Full Text] [Related]
50. Glargine safety, diabetes and cancer.
Rendell M; Akturk HK; Tella SH
Expert Opin Drug Saf; 2013 Mar; 12(2):247-63. PubMed ID: 23394441
[TBL] [Abstract][Full Text] [Related]
51. Insulin glargine.
Campbell RK; White JR; Levien T; Baker D
Clin Ther; 2001 Dec; 23(12):1938-57; discussion 1923. PubMed ID: 11813930
[TBL] [Abstract][Full Text] [Related]
52. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
Davies M; Evans R; Storms F; Gomis R; Khunti K
Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
[TBL] [Abstract][Full Text] [Related]
53. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP
Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850
[TBL] [Abstract][Full Text] [Related]
54. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Riddle MC; Rosenstock J; Gerich J;
Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
[TBL] [Abstract][Full Text] [Related]
55. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
Beaudet A; Palmer JL; Timlin L; Wilson B; Bruhn D; Boye KS; Lloyd A
J Med Econ; 2011; 14(3):357-66. PubMed ID: 21563878
[TBL] [Abstract][Full Text] [Related]
56. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
57. Dualities of interest are not restricted to financial ties to the pharmaceutical industry.
Nauck M
Diabetologia; 2010 Jan; 53(1):212-3. PubMed ID: 19921143
[No Abstract] [Full Text] [Related]
58. Mitogenic action of insulin: friend, foe or 'frenemy'?
Draznin B
Diabetologia; 2010 Feb; 53(2):229-33. PubMed ID: 19851749
[TBL] [Abstract][Full Text] [Related]
59. Diabetes therapy and cancer risk: causal effects and other plausible explanations.
Hernández-Díaz S; Adami HO
Diabetologia; 2010 May; 53(5):802-8. PubMed ID: 20177658
[TBL] [Abstract][Full Text] [Related]
60. Long-Term Glucocorticoid Use and Cancer Risk: A Population-Based Cohort Study in South Korea.
Oh TK; Song IA
Cancer Prev Res (Phila); 2020 Dec; 13(12):1017-1026. PubMed ID: 32839205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
